# Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Non-Small Cell Lung Cancer

> **NCT00673777** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Tokyo University** · enrollment: 14 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **BIOLOGICAL:** URLC10, VEGFR1 and VEGFR2

## Key facts

- **NCT ID:** NCT00673777
- **Lead sponsor:** Tokyo University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2008-05
- **Primary completion:** 2009-04
- **Final completion:** 2009-04
- **Target enrollment:** 14 (ESTIMATED)
- **Last updated:** 2008-05-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00673777

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00673777, "Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00673777. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*